DOCSLIB.ORG

Opioid Receptor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Opioid Receptor A tetrapeptide class of biased analgesics from an Australian fungus targets the μ-opioid receptor Zoltan Dekana,1, Setareh Sianatib,1, Arsalan Yousufb,1, Katy J. Sutcliffec,1, Alexander Gillisb, Christophe Malletb,2, Paramjit Singha, Aihua H. Jina, Anna M. Wangb, Sarasa A. Mohammadib, Michael Stewarta, Ranjala Ratnayakea, Frank Fontainea, Ernest Laceyd, Andrew M. Piggotta, Yan P. Dub, Meritxell Canalse,3, Richard B. Sessionsc, Eamonn Kellyc, Robert J. Capona,4, Paul F. Alewooda,4, and MacDonald J. Christieb,4 aInstitute for Molecular Bioscience, The University of Queensland, 4072 Brisbane, Australia; bDiscipline of Pharmacology, School of Medical Sciences, University of Sydney, NSW 2006, Australia; cSchools of Physiology, Pharmacology and Neuroscience, and Biochemistry, Biomedical Sciences Building, University of Bristol, BS8 1TD Bristol, United Kingdom; dMicrobial Screening Technologies Pty. Ltd., Smithfield, NSW, 2164, Australia; and eDrug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 3052 Parkville, Australia Edited by Robert J. Lefkowitz, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC, and approved September 18, 2019 (received for review May 22, 2019) An Australian estuarine isolate of Penicillium sp. MST-MF667 yielded in the second position formed by a posttranslational modification 3 tetrapeptides named the bilaids with an unusual alternating LDLD isolated from frog skin, dermorphin and deltorphin II, selectively chirality. Given their resemblance to known short peptide opioid target MOPr and DOPr, respectively (14). Similar synthetic modi- K agonists, we elucidated that they were weak ( i low micromolar) fications have yielded enhanced biological stability and receptor μ-opioid agonists, which led to the design of bilorphin, a potent and selectivity. For example, introduction of D-Ala stabilizes the en- μ K selective -opioid receptor (MOPr) agonist ( i 1.1 nM). In sharp con- kephalins to proteolysis, and further substitutions yield highly trast to all-natural product opioid peptides that efficaciously recruit stable, selective MOPr agonists such as DAMGO ([D-Ala2, N- β-arrestin, bilorphin is G protein biased, weakly phosphorylating MePhe4, Gly5-ol]-enkephalin) (15). However, to our knowledge, all the MOPr and marginally recruiting β-arrestin, with no receptor endogenous opioid peptides acting on MOPr robustly recruit internalization. Importantly, bilorphin exhibits a similar G protein arrestins and produce MOPr internalization (16–19). Here, we re- bias to oliceridine, a small nonpeptide with improved overdose port the discovery of 3 tetrapeptides, bilaids A–C(Fig.1,[1a-3a]), PHARMACOLOGY safety. Molecular dynamics simulations of bilorphin and the from an Australian estuarine isolate of Penicillium sp. MST-MF667 strongly arrestin-biased endomorphin-2 with the MOPr indicate distinct receptor interactions and receptor conformations that Significance could underlie their large differences in bias. Whereas bilorphin is systemically inactive, a glycosylated analog, bilactorphin, is μ orally active with similar in vivo potency to morphine. Bilorphin Agonists of the -opioid receptor (MOPr) are currently the gold is both a unique molecular tool that enhances understanding of standard for pain treatment. However, their therapeutic usage is MOPr biased signaling and a promising lead in the development of greatly limited by side effects including respiratory depression, next generation analgesics. constipation, tolerance, and dependence. Functionally selective MOPr agonists that mediate their effects preferentially through β biased agonist | μ-opioid receptor | peptide drug | opioid analgesic | G proteins rather than -arrestin signaling are believed to pro- glycosylation duce fewer side effects. Here, we present the discovery of 3 unusual tetrapeptides with a unique stereochemical arrange- ment of hydrophobic amino acids from an Australian estuarine eveloping ligands that target G protein-coupled receptors isolate of Penicillium species. Building on these natural tem- D(GPCRs) in multiple functional states has attracted great plates we developed bilorphin, a potent and selective highly G interest, particularly with increasing knowledge of GPCR struc- – protein-biased agonist of the MOPr. Further, through the addi- ture (1 3). These novel ligands are expected to underpin the tion of a simple sugar moiety, we generated bilactorphin that is development of agonists with superior pharmaceutically relevant an effective analgesic in vivo. properties, including biased receptor signaling (4, 5), whereby one downstream signaling pathway is favored over another. For Author contributions: Z.D., A.Y., A.G., C.M., A.M.W., S.A.M., M.C., R.B.S., E.K., R.J.C., P.F.A., example, biased agonists that signal by differentially recruiting G and M.J.C. designed research; Z.D., S.S., A.Y., K.J.S., A.G., C.M., P.S., A.H.J., A.M.W., S.A.M., proteins over β-arrestin to the μ-opioid receptor (MOPr) could M.S., R.R., F.F., E.L., A.M.P., and Y.P.D. performed research; E.L. contributed new reagents/ analytic tools; Z.D., S.S., A.Y., K.J.S., A.G., C.M., P.S., A.H.J., A.M.W., S.A.M., M.S., R.R., F.F., deliver better analgesics, based on the view that down-regulating A.M.P., Y.P.D., M.C., R.B.S., E.K., R.J.C., P.F.A., and M.J.C. analyzed data; and Z.D., S.S., β-arrestin recruitment diminishes adverse side effects (4, 6–8). A.Y., K.J.S., A.G., S.A.M., M.C., R.B.S., E.K., R.J.C., P.F.A., and M.J.C. wrote the paper. Exploiting this concept, the G protein-biased MOPr agonist Competing interest statement: Patent Application(s) corresponding to Australian Patent oliceridine (TRV130) is a potent analgesic in rodents, with lower Application 2018901944 The University of Sydney and The University of Queensland has respiratory depression and gastrointestinal dysfunction compared been filed concerning this peptide. Title: Analgesics and Methods of Use Thereof. to morphine (7). Indeed, human clinical trials of oliceridine show This article is a PNAS Direct Submission. reduced respiratory impairment compared to morphine adminis- This open access article is distributed under Creative Commons Attribution-NonCommercial- NoDerivatives License 4.0 (CC BY-NC-ND). tered at equi-analgesic doses (9). Reduced respiratory depression 1 delivers improved safety, potentially reducing the burden of opioid Z.D., S.S., A.Y., and K.J.S. contributed equally to this work. 2 overdoses, now at epidemic proportions in many jurisdictions (10). Present address: Neuro-Dol Basics & Clinical Pharmacology of Pain, INSERM, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France. Bioactive peptides display great promise for their novel phar- 3Present address: Centre of Membrane Proteins and Receptors, University of Nottingham, macological properties (11). Since the discovery of the relatively NG7 2UH Nottingham, United Kingdom. nonselective mammalian opioid peptides, the enkephalins, other 4To whom correspondence may be addressed. Email: [email protected], endogenous mammalian ligands, including the tetrapeptide [email protected], or [email protected]. endomorphins that target the MOPr with high selectivity over This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. the related κ-opioid (KOPr) and δ-opioid (DOPr) subtypes, have 1073/pnas.1908662116/-/DCSupplemental. been found (12, 13). Natural peptide agonists containing a D-Ala www.pnas.org/cgi/doi/10.1073/pnas.1908662116 PNAS Latest Articles | 1of6 Downloaded by guest on September 29, 2021 [initially reported as P. bilaii (20); maximum likelihood tree pre- A B sented in SI Appendix,Fig.S1]. Discovery of the bilaids, which re- YvVf-OH (3a) met-enk bilorphin YvYf-NH2 (3b) CTAP semble known opioid peptides but featuring an unusual alternating 100 [Dmt]-vVf-NH2 (3c, MOPr) sequence of antipodal amino acids (LDLD), led to our design of [Dmt]-vVf-NH2 (DOPr) [Dmt]-vVf-NH2 (KOPr) bilorphin (3c), a MOPr agonist, with G protein signaling bias similar 75 to oliceridine. Bilorphin adopts a distinct conformational shape and C 50 intermolecular interactions in molecular dynamics (MD) simula- (nS) – GIRK tions of the bilorphin MOPr complex, consistent with predicted G 25 G Specific binding (%) protein bias at related GPCRs. Together with its in vitro and in vivo 0 1 μM 10030 300 1010 activity, we demonstrate that bilorphin provides a scaffold for the -10-9-8-7-6-5-4 SST bilorphin morph Met-enk development of stable, orally active opioid peptides that are biased log [agonist] (M) (nM) (μM) (μM) toward G protein signaling (3g). D E 125 100 Results 100 75 To date, the major opioid peptide families have only been de- tected in vertebrates (21). Through a broader screening program, 75 50 we now report the discovery of 3 closely related tetrapeptides % of 1μM SST) GIRK current 50 (Fig. 1), bilaids A (1a, FvVf-OH), B (2a, FvVy-OH), and C (3a, ( (% of 1 μM Met-enk ) GIRK 25 25 YvVf-OH), from the Australian estuarine-derived Penicillium sp. G MST-MF667. Solvent extracts of cultivations of MST-MF667 0 0 -8 -7 -6 -5 -9 -8 -7 -6 -5 were subjected to solvent partition followed by reversed-phase log [agonist] (M) log [agonist] (M) high-performance liquid chromatography (HPLC) to yield 1a met-enk (0.15%), as well as traces of 2a (0.0018%) and 3a (0.0008%) morphine endo-2 bilorphin oliceridine (Fig. 1). The chemical structures for 1a–3a, which resemble Fig. 2. (A) Competition for binding of [3H]DAMGO to hMOPr (human opioid peptides albeit with a unique, alternating LDLD amino recombinant MOPr) by the native bilaid YvVf-OH (3a), YvVf-NH2 (3b)and 3 acid configuration, were identified by spectroscopic analyses, bilorphin ([Dmt]vVf-NH2)(3c), as well as bilorphin to hDOPr ([ H]DADLE 3 chemical derivatization and degradation, and Marfey’sanalysis binding to human recombinant DOPr) and hKOPr ([ H] U69593 binding to and total synthesis. In addition to synthesizing 1a–3a,wepre- human recombinant KOPr).
Load more

Recommended publications
  • Ong Edmund W 201703 Phd.Pdf (5.844Mb)
    INVESTIGATING THE EFFECTS OF PROLONGED MU OPIOID RECEPTOR ACTIVATION UPON OPIOID RECEPTOR HETEROMERIZATION by Edmund Wing Ong A thesis submitted to the Graduate Program in Pharmacology & Toxicology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Doctor of Philosophy Queen’s University Kingston, Ontario, Canada March, 2017 Copyright © Edmund Wing Ong, 2017 Abstract Opioid receptors are the sites of action for morphine and most other clinically-used opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers. Owing to their constituent monomers’ involvement in analgesia, mu/delta opioid receptor (M/DOR) heteromers have been a particular focus of attention. Understandings of the physiological relevance of M/DOR formation remain limited in large part due to the reliance of existing M/DOR findings upon contrived heterologous systems. This thesis investigated the physiological relevance of M/DOR generation following prolonged MOR activation. To address M/DOR in endogenous tissues, suitable model systems and experimental tools were established. This included a viable dorsal root ganglion (DRG) neuron primary culture model, antisera specifically directed against M/DOR, a quantitative immunofluorescence colocalizational analysis method, and a floxed-Stop, FLAG-tagged DOR conditional knock-in mouse model. The development and implementation of such techniques make it possible to conduct experiments addressing the nature of M/DOR heteromers in systems with compelling physiological relevance. Seeking to both reinforce and extend existing findings from heterologous systems, it was first necessary to demonstrate the existence of M/DOR heteromers. Using antibodies directed against M/DOR itself as well as constituent monomers, M/DOR heteromers were identified in endogenous tissues and demonstrated to increase in abundance following prolonged mu opioid receptor (MOR) activation by morphine.
    [Show full text]
  • Example of a Scientific Poster
    Janet Robishaw, PhD Senior Associate Dean for Research Chair and Professor, Biomedical Science Florida Atlantic University Charles E. Schmidt College of Medicine Disclosures and Conflicts • I have no actual or potential conflict of interest in relation to this program/presentation. • Research support: Robishaw, MPI Robishaw, MPI R01 DA044015 R01 HL134015 Genetic Predictors of Opioid Addiction Genetic Heterogeneity of Sleep Apnea 2017-2022 2016-2021 Robishaw, PI Robishaw, MPI R01 GM114665 R01 GM111913 Novel Aspects of Golf Signaling GPCR Variants in Complex Diseases 2015-2019 2015-2019 Learning Objectives 1. Review the scope and root cause of opioid use disorder 2. Discuss the effects of opioid medications on the brain and body 3. Stress the importance of clinical judgement and discovery to address the opioid crisis 4. Highlight the clinical implications between opioid use disorder and heroin abuse Two Endemic Problems Chronic Pain Opioid Use Disorder Debilitating disorder Chronic, relapsing disorder 100 million Americans 2 million Americans Costs $630 billion dollars per year Costs $80 billion per year #1 presenting complaint to doctors # 1 cause of accidental death #1 reason for lost productivity #1 driver of heroin epidemic #1 treatment –opioid medications ? treatment Pain Relief and “Addiction” Share A Common Mechanism of Action m-Opioid Receptor Brain Regions Involved in Pleasure and Reward Increase dopamine release Brain Regions Involved in Pain Perception Brainstem Involved in Respiratory Control Spinal Cord Involved in Pain Transmission Prevent ascending transmission Turn on descending inhibitory systems These receptors are dispersed Inhibit peripheral nocioceptors throughout the body, thereby accounting for their differential Body effects on pain and reward paths.
    [Show full text]
  • Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
    molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs.
    [Show full text]
  • An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional D
    J Mol Cell Cardiol 32, 2187–2193 (2000) doi:10.1006/jmcc.2000.1241, available online at http://www.idealibrary.com on An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor Claire L. Neilan1, Erin Kenyon1, Melissa A. Kovach1, Kristin Bowden1, William C. Claycomb2, John R. Traynor3 and Steven F. Bolling1 1Department of Cardiac Surgery, University of Michigan, B558 MSRB II, Ann Arbor, MI 48109-0686, USA, 2Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, LA 70112, USA and 3Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632, USA (Received 17 March 2000, accepted in revised form 30 August 2000, published electronically 25 September 2000) C. L. N,E.K,M.A.K,K.B,W.C.C,J.R.T S. F. B.An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor. Journal of Molecular and Cellular Cardiology (2000) 32, 2187–2193. The present study characterizes opioid receptors in an immortalized myocyte cell line, HL-1. Displacement of [3H]bremazocine by selective ligands for the mu (), delta (), and kappa () receptors revealed that only the -selective ligands could fully displace specific [3H]bremazocine binding, indicating the presence of only the -receptor in these cells. Saturation binding studies with the -antagonist naltrindole 3 afforded a Bmax of 32 fmols/mg protein and a KD value for [ H]naltrindole of 0.46 n. The binding affinities of various ligands for the receptor in HL-1 cell membranes obtained from competition binding assays were similar to those obtained using membranes from a neuroblastoma×glioma cell line, NG108-15.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • Kappa Opioid Receptor Regulation of Erk1/2 Map Kinase Signaling Cascade
    1 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD A dissertation presented by Khampaseuth Rasakham to The Department of Psychology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Psychology Northeastern University Boston, Massachusetts August, 2008 2 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD by Khampaseuth Rasakham ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Psychology in the Graduate School of Arts and Sciences of Northeastern University, August, 2008 3 ABSTRACT Activation of the Kappa Opioid Receptor (KOR) modulates dopamine (DA) signaling, and Extracellular Regulated Kinase (ERK) Mitogen-Activated Protein (MAP) kinase activity, thereby potentially regulating the rewarding effects of cocaine. The central hypothesis to be tested is that the time-and drug-dependent KOR-mediated regulation of ERK1/2 MAP kinase activity occurs via distinct molecular mechanisms, which in turn may determine the modulation (suppression or potentiation) by KOR effects on cocaine conditioned place preference (CPP). Three studies were performed to test this hypothesis. Study 1 examined the effects of U50,488 and salvinorin A on cocaine reward. In these studies, mice were treated with equianalgesic doses of agonist from 15 to 360 min prior to daily saline or cocaine place conditioning. At time points corresponding with peak biological activity, both agonists produced saline-conditioned place aversion and suppressed cocaine-CPP, effects blocked by the KOR antagonist nor-BNI. However, when mice were place conditioned with cocaine 90 min after agonist pretreatment, U50,488-pretreated mice demonstrated a 2.5-fold potentiation of cocaine-CPP, whereas salvinorin A-pretreated mice demonstrated normal cocaine-CPP responses.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides
    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
    [Show full text]
  • Pain Therapy E Are There New Options on the Horizon?
    Best Practice & Research Clinical Rheumatology 33 (2019) 101420 Contents lists available at ScienceDirect Best Practice & Research Clinical Rheumatology journal homepage: www.elsevierhealth.com/berh 4 Pain therapy e Are there new options on the horizon? * Christoph Stein a, , Andreas Kopf b a Department of Experimental Anesthesiology, Charite Campus Benjamin Franklin, D-12200 Berlin, Germany b Department of Anesthesiology and Intensive Care Medicine, Charite Campus Benjamin Franklin, D-12200 Berlin, Germany abstract Keywords: Opioid crisis This article reviews the role of analgesic drugs with a particular Chronic noncancer pain emphasis on opioids. Opioids are the oldest and most potent drugs Chronic nonmalignant pain for the treatment of severe pain, but they are burdened by detri- Opioid mental side effects such as respiratory depression, addiction, Opiate sedation, nausea, and constipation. Their clinical application is Inflammation undisputed in acute (e.g., perioperative) and cancer pain, but their Opioid receptor long-term use in chronic pain has met increasing scrutiny and has Misuse Abuse contributed to the current opioid crisis. We discuss epidemiolog- Bio-psycho-social ical data, pharmacological principles, clinical applications, and research strategies aiming at novel opioids with reduced side effects. © 2019 Elsevier Ltd. All rights reserved. The opioid epidemic The treatment of pain remains a huge challenge in clinical medicine and public health [1,2]. Pain is the major symptom in rheumatoid (RA) and osteoarthritis (OA) [3,4]. Both are chronic conditions that are not linked to malignant disease, and pain can occur even in the absence of inflammatory signs (see chapter “Pain without inflammation”). Unfortunately, there is a lack of fundamental knowledge about the management of chronic noncancer pain.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Dynorphin Induces Task-Specific Impairment of Memory
    Psychobiology 1987, Vol. 15 (2), 171-174 Dynorphin induces task-specific impairment of memory INES B. INTROINI-COLLISON and LARRY CAHILL University of California, Irvine, California CARLOS M. BARATTl Universidad de Buenos Aires, Buenos Aires, Argentina and JAMES L. McGAUGH University of California, Irvine, California Immediate posttraining administration of the opioid peptide dynorphin(1-13) (0.1, 0.3, and 1.0l'g/kg i.p.) significantly impaired 24-h retention of a one-trial inhibitory avoidance task in mice. In contrast, posttraining dynorphin did not modify retention of either a Y-maze discrimi- nation (0.1, 1.0, or 10.0I'g/kg i.p.) or habituation of exploration (0.1, 0.3, 1.0, or 2.0 I'g/kg i.p.). The administration of dynorphin (0.1, 1.0, and 10.0I'g/kg i.p.) 2 min prior to the inhibitory avoidance retention test did not modify retention latencies of mice injected with either saline or dynorphin (O.ll'g/kg i.p.) immediately after training. In mice, dynorphin appears to impair retention by interfering with memory storage processes, and this effect seems to be task specific. There are three families of opioid peptides in the brain: range studied by Izquierdo et al. (1985). Interestingly, the ,B-endorphins, the enkephalins, and the dynorphins Castellano and Pavone (in press) showed that posttrain- (Akil et al., 1984; Weber, Evans, & Barchas, 1983). Re- ing administration of the x-opioid receptor agonist ports from many different laboratories have shown that bremazocine impairs retention of an inhibitory avoidance in rats and mice posttraining administration of ,6-endorphin task in DBA/2 mice, and that this effect is time- and dose- or the enkephalins produces retrograde amnesia in a wide dependent.
    [Show full text]